135 related articles for article (PubMed ID: 15840902)
1. Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease.
Matsunaga T; Chilian WM; March K
Am J Physiol Heart Circ Physiol; 2005 May; 288(5):H2042-6. PubMed ID: 15840902
[TBL] [Abstract][Full Text] [Related]
2. Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation.
Sodha NR; Clements RT; Boodhwani M; Xu SH; Laham RJ; Bianchi C; Sellke FW
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H428-34. PubMed ID: 19074676
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature.
Chung AW; Hsiang YN; Matzke LA; McManus BM; van Breemen C; Okon EB
Circ Res; 2006 Jul; 99(2):140-8. PubMed ID: 16778129
[TBL] [Abstract][Full Text] [Related]
4. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease.
Panchal VR; Rehman J; Nguyen AT; Brown JW; Turrentine MW; Mahomed Y; March KL
J Am Coll Cardiol; 2004 Apr; 43(8):1383-7. PubMed ID: 15093871
[TBL] [Abstract][Full Text] [Related]
5. Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin.
Weihrauch D; Lohr NL; Mraovic B; Ludwig LM; Chilian WM; Pagel PS; Warltier DC; Kersten JR
Circulation; 2004 May; 109(19):2343-8. PubMed ID: 15136506
[TBL] [Abstract][Full Text] [Related]
6. Impaired coronary collateral growth in the metabolic syndrome is in part mediated by matrix metalloproteinase 12-dependent production of endostatin and angiostatin.
Dodd T; Wiggins L; Hutcheson R; Smith E; Musiyenko A; Hysell B; Russell JC; Rocic P
Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1339-49. PubMed ID: 23599440
[TBL] [Abstract][Full Text] [Related]
7. The effect of hypoxia on plasma angiostatin and related factors in newborn pigs.
Emara M; Obaid L; Johnson S; Bigam DL; Cheung PY
Proc West Pharmacol Soc; 2007; 50():47-52. PubMed ID: 18605228
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen.
Brauer R; Beck IM; Roderfeld M; Roeb E; Sedlacek R
BMC Biochem; 2011 Jul; 12():38. PubMed ID: 21787393
[TBL] [Abstract][Full Text] [Related]
9. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide.
Matsunaga T; Weihrauch DW; Moniz MC; Tessmer J; Warltier DC; Chilian WM
Circulation; 2002 May; 105(18):2185-91. PubMed ID: 11994253
[TBL] [Abstract][Full Text] [Related]
10. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure.
Basile DP; Fredrich K; Weihrauch D; Hattan N; Chilian WM
Am J Physiol Renal Physiol; 2004 May; 286(5):F893-902. PubMed ID: 15075185
[TBL] [Abstract][Full Text] [Related]
11. [The role of angiostatin, vascular endothelial growth factor, matrix metalloproteinase 9 and 12 in the angiogenesis of hepatocellular carcinoma].
Kim S; Park HS; Son HJ; Moon WS
Korean J Hepatol; 2004 Mar; 10(1):62-72. PubMed ID: 15096718
[TBL] [Abstract][Full Text] [Related]
12. Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion.
Tyagi SC; Kumar S; Cassatt S; Parker JL
Can J Physiol Pharmacol; 1996 Aug; 74(8):983-95. PubMed ID: 8960389
[TBL] [Abstract][Full Text] [Related]
13. Angiostatin inhibits endothelial MMP-2 and MMP-14 expression: a hypoxia specific mechanism of action.
Radziwon-Balicka A; Ramer C; Moncada de la Rosa C; Zielnik-Drabik B; Jurasz P
Vascul Pharmacol; 2013 Apr; 58(4):280-91. PubMed ID: 23220260
[TBL] [Abstract][Full Text] [Related]
14. Angiostatin does not contribute to skeletal muscle microvascular rarefaction with low nitric oxide bioavailability.
Frisbee JC; Samora JB; Basile DP
Microcirculation; 2007 Feb; 14(2):145-53. PubMed ID: 17365669
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of angiostatin in effusions from patients with malignant disease.
Rotenberg RG; Rozas NS; Guerri L; Cher ML; Gamboni M; Lema N; Bonfil RD
Oncol Rep; 2004 Feb; 11(2):523-8. PubMed ID: 14719094
[TBL] [Abstract][Full Text] [Related]
16. Angiostatins decrease in the kidney of newborn piglets after hypoxia-reoxygenation.
Emara M; Obaid L; Johnson S; Bigam DL; Cheung PY
Eur J Pharmacol; 2010 Oct; 644(1-3):203-8. PubMed ID: 20621087
[TBL] [Abstract][Full Text] [Related]
17. Coronary collaterals: the role of MCP-1 during the early phase of acute myocardial infarction.
Park HJ; Chang K; Park CS; Jang SW; Ihm SH; Kim PJ; Baek SH; Seung KB; Choi KB
Int J Cardiol; 2008 Nov; 130(3):409-13. PubMed ID: 18158188
[TBL] [Abstract][Full Text] [Related]
18. The relationship of plasma miR-503 and coronary collateral circulation in patients with coronary artery disease.
Fei Y; Hou J; Xuan W; Zhang C; Meng X
Life Sci; 2018 Aug; 207():145-151. PubMed ID: 29870767
[TBL] [Abstract][Full Text] [Related]
19. Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients.
Sodha NR; Boodhwani M; Clements RT; Xu SH; Khabbaz KR; Sellke FW
Arch Surg; 2008 May; 143(5):463-70. PubMed ID: 18490555
[TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular factors responsible for coronary collateral formation.
Sherman JA; Hall A; Malenka DJ; De Muinck ED; Simons M
Am J Cardiol; 2006 Nov; 98(9):1194-7. PubMed ID: 17056326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
